Education and Training

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

The study hypothesis is that dextro-amphetamine (d-amphetamine) will be safe and effective when used to augment treatment for Obsessive-Compulsive Disorder (OCD), and that tolerance (loss of therapeutic effect) to the medication will not develop over a period of several weeks.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: dextro-amphetamine
  • drug: Sham Comparison

Eligibility


Inclusion Criteria:

   - outpatient age 18 through 55 inclusive

   - meets DSM-IV criteria for obsessive-compulsive disorder (OCD) with Yale-Brown
   Obsessive-Compulsive Scale (YBOCS) score greater than or equal to 20

   - provides written informed consent

   - has taken for at least 12 weeks at least the dose shown of a selective serotonin
   reuptake inhibitor (SSRI) [citalopram, escitalopram, or fluoxetine 20 mg/d; paroxetine
   40 mg/d; sertraline 50 mg/d]; or venlafaxine 225 mg/d; or duloxetine 60 mg/d.

   - if taking buspar, gabapentin, an atypical antipsychotic, or a benzodiazepine, dose has
   been stable for 4 weeks

   - has negative urine drug and pregnancy tests

   - is practicing reliable birth control method

   - has blood pressure readings at screening visit that are less than 140 mm Hg systolic
   and 90 mm Hg diastolic,

   - weight is greater than 100 lbs at screen

Exclusion criteria:

   - requires psychotropic medications other than an Serotonin Reuptake Inhibitor (SRI), a
   benzodiazepine, buspirone, an atypical antipsychotic, and/or gabapentin

   - is taking clomipramine

   - is taking fluvoxamine

   - is taking medication that inhibits hepatic enzyme CYP1A2

   - is taking a monoamine oxidase inhibitor

   - has co-morbid tics or Tourette's disorder

   - has hoarding as the primary or only OCD symptom

   - has a history of panic disorder

   - has a history of glaucoma

   - has a history of seizures

   - has a history of schizophrenia or psychotic disorder, or schizotypal personality
   disorder

   - has depression with current suicide risk

   - has mental retardation, pervasive developmental disorder, or cognitive disorder

   - has a factitious disorder

   - has current or past cyclothymic disorder or bipolar disorder

   - has a dissociative disorder

   - has personality disorder sufficient to interfere with study participation

   - has organic mental disorder or dementia

   - has current or past substance abuse / dependence (excluding nicotine)

   - has current or past anorexia or bulimia

   - has serious or unstable medical disorder, including hypertension or cardiac disease

   - has history of myocardial infarction or cardiac arrhythmia

   - has history of or has current diagnosis of hypertension

   - is pregnant or breast-feeding

   - is receiving psychotherapy for OCD

   - is intending to receive psychotherapy for OCD during the study

   - has had a previous trial of d-amphetamine of at least 30 days duration

   - is unable to speak, read, or understand English

   - is not likely to follow study procedures

   - is not suitable for study in the investigator's opinion

Ages Eligible for Study

18 Years - 55 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Lorrin Koran
6507235154
Not Recruiting